HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says
FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients
You may also be interested in...
FDA's oncology division is interested in revisiting the accelerated approval regulations as they apply to cancer treatments
Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions
Modified factorial trial designs are the best strategy for studying new therapies in heavily treated HIV patients, FDA's Antiviral Drugs Advisory Committee suggested.